title: Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
abstract: BACKGROUND
  Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established.
  
  
  METHODS
  We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin. During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested. Tandem high-dose ICE regimen (ifosfamide 3 g/m2 on days-7 to -3, carboplatin 400 mg/m2 on days-7, -5 and 3, etoposide 500 mg/m2 on days-7, -5 and 3) supported by autologous PBSCT gave rise to further regression of the tumors. Another patient with malignant hemangiopericytoma was treated by tandem high-dose ICE regimen supported by autologous PBSCT after the 3rd removal of abdominal tumors. Relapse-free intervals until the 1st, 2nd and 3rd relapses were 40, 19 and 22 months, respectively. Tandem high-dose ICE regimen might delay the relapse.
  
  
  CONCLUSIONS
  These observations suggest that a tandem high-dose ICE regimen with autologous PBSCT is feasible with some clinical efficacy in the control of refractory STS.
authors.affiliation: Second Department of Internal Medicine, Okayama University Medical School, 2-5-1 Shikatacho, Okayama 700-8558, Japan. kozuka@md.okayama-u.ac.jp
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Kozuka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Hideki
authors.initials: H
authors.lastname: Katayama
authors.forename: Nobuharu
authors.initials: N
authors.lastname: Fujii
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ishimaru
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueoka
authors.forename: Shuuji
authors.initials: S
authors.lastname: Hamasaki
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kashihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Date
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000628:therapy*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000628:therapy; D012509:Sarcoma / Q000188:drug therapy / Q000628:therapy*
chemical_list: D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide